The p53 tumor suppressor transcriptionally regulates a myriad of genes involved in cell cycle control, DNA repair, cell survival, and cell metabolism and represents one of the most well‐studied inhibitors of tumorigenesis. Since the discovery of TP53 in 1979, somatic mutations have been shown to be extremely common; more than 50% of human cancers carry loss‐of‐function mutations in TP53. Inherited or germline TP53 mutations are rare and are involved in complex hereditary cancer predisposition disorders,...
Mon Aug 17, 2020 17:55
Cancer Biotherapy and Radiopharmaceuticals, Volume 35, Issue 6, Page 446-458, August 2020.
Thu Aug 13, 2020 10:00
Abstract A recent outbreak of coronavirus disease 19 (COVID‐19) caused by the novel severe acute respiratory coronavirus 2 (SARS‐CoV‐2) has driven a global pandemic with catastrophic consequences. The rapid development of promising therapeutic strategies against COVID‐19 is keenly anticipated. Family Coronaviridae comprises positive, single‐stranded RNA viruses that use RNA‐dependent RNA polymerase (RdRP) for viral replication and transcription. Since the RdRP of viruses in this family and others...
Mon Aug 17, 2020 14:14
Purpose: Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment. Experimental Design: Prospectively defined retrospective correlative exploratory analyses tested biospecimens from 52 treatment-naïve patients receiving axitinib and pembrolizumab (starting doses 5 mg twice-daily and 2 mg/kg every 3 weeks). Tumor tissue,...
Tue Aug 18, 2020 16:20
Purpose: 90Y-FF-21101 is an Yttrium-90-conjugated, chimeric monoclonal antibody that is highly-specific for binding to human P-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination in many cancer types. We report the clinical activity of 90Y-FF-21101 in a first-in-human Phase I study in patients with advanced solid tumors. Patients and Methods: The safety and efficacy of 90Y-FF-21101 were evaluated in a Phase 1 3+3 dose-escalation...
Tue Aug 18, 2020 16:20
Purpose: Risk of myeloma (MM) is increased in African American (AA) populations compared to European American (EA) cohorts. Current estimates of risk of progression of monoclonal gammopathy of undetermined significance (MGUS) are based largely on studies in EA cohorts. Prospective analyses of this risk in AA cohorts are lacking. Patients and Methods: Between 2003 and 2011, 331 eligible patients with IgG/A monoclonal gammopathy were enrolled in a prospective observational trial (SWOG S0120). Results:...
Tue Aug 18, 2020 16:20
Purpose: High grade gliomas are central nervous system tumors with poor prognoses and limited treatment options. Vocimagene amiretrorepvec (Toca 511) is a retroviral replicating vector encoding cytosine deaminase, which converts extended-release 5-fluorocytosine (Toca FC) into the anti-cancer agent 5-fluorouracil. According to preclinical studies, this therapy kills cancer cells and immunosuppressive myeloid cells in the tumor microenvironment, leading to T-cell mediated anti-tumor immune activity....
Tue Aug 18, 2020 16:20
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T cell receptor binding domain, and an anti-CD3 T cell engaging domain which redirects T cells to kill gp100-expressing tumor cells. Here we report from a multicentre Phase 1/2 trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp Experimental Design: 84 patients with advanced melanoma received tebentafusp....
Tue Aug 18, 2020 16:20
COVID-19 has fundamentally disrupted the practice of oncology, shifting care onto virtual platforms, rearranging the logistics and economics of running a successful clinical practice and research, and in some contexts, redefining what treatments cancer patients should and can receive. Since the start of the pandemic in early 2020, there has been the considerable emphasis placed on the implications for cancer patients in terms of their vulnerability to the virus and potential exposure in healthcare...
Tue Aug 18, 2020 16:20
Purpose: A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To better understand the mechanism of action and to identify predictive biomarkers, immunological and viral correlates were assessed before, during, and after treatment. Experimental Design: Twenty-one patients...
Tue Aug 18, 2020 16:20
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Claudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, Giulia Martini, Vittorio Simeon, Pietro P. Vitiello, Davide Ciardiello, Valentina Belli, Nunzia Matrone, Teresa Troiani, Floriana Morgillo, Federica Zito Marino, Monica Dentice, Annarita Nappi, Alessandra Boccaccino, Carlotta Antoniotti, Chiara Cremolini, Filippo Pietrantonio, Gerald W. Prager, Nicola Normanno
Tue Aug 18, 2020 16:08
Publication date: Available online 18 August 2020Source: European Journal of Surgical OncologyAuthor(s): Gianluca Pellino, Rafael Alós, Sebastiano Biondo, Antonio Codina-Cazador, José María Enríquez-Navascues, Eloy Espín-Basany, José Vicente Roig-Vila, Andrés Cervantes, Eduardo García-Granero, Raúl Adell Carceller, Juan Guillermo Ais Conde, Evelio Alonso Alonso, Antonio Amaya Cortijo, Antonio Arroyo Sebastian, Pedro Barra Baños, Ricard Batlle Solé, Juan C. Bernal Sprekelsen, Sebastiano Biondo, Francisco...
Tue Aug 18, 2020 17:43
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 12:42
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 12:32
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 12:16
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 12:08
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 11:45
Future Oncology, Ahead of Print.
Mon Aug 17, 2020 11:20
Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials. Future Oncol. 2020 Aug 17;: Authors: Lavalle C, V Mariani M, Fedele F PMID: 32805155 [PubMed - as supplied by publisher]
Tue Aug 18, 2020 15:31
Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer. Future Oncol. 2020 Aug 17;: Authors: Bayraktar S, Batoo S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract There are three US FDA-approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question...
Tue Aug 18, 2020 15:31
Targeting HER2 in the management of potentially resectable gastric adenocarcinoma: what are oncologists waiting for? Future Oncol. 2020 Aug 17;: Authors: Gharib KE, R Kourie H PMID: 32805125 [PubMed - as supplied by publisher]
Tue Aug 18, 2020 15:31
Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol. 2020 Aug 17;: Authors: Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA Abstract Cancer is one of the leading causes of death worldwide. Regardless of advances in understanding the molecular mechanics of cancer, its treatment is still lacking and the death rates for many forms of the disease remain the same as six decades ago. Although a...
Tue Aug 18, 2020 15:31
Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis. Future Oncol. 2020 Aug 17;: Authors: Zhang F, Cui JY, Gao HF, Yu H, Gao FF, Chen JL, Chen L Abstract Aim: Cancer-associated fibroblasts (CAFs) are closely related to epithelial-mesenchymal transition (EMT) and chemoresistance in various cancers. Patients & methods: Experiments in vivo and retrospective...
Tue Aug 18, 2020 15:31
Related Articles A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer. Future Oncol. 2020 Aug 17;: Authors: Verdaguer H, Acosta D, Macarulla T Abstract Pancreatic cancer has a poor prognosis. Focused efforts in the development of novel treatments of this disease have led to the approval of new combinations. Improvements in knowledge of the biology of these tumors have been made, and it is now widely...
Tue Aug 18, 2020 15:31
Abstract Helicobacter pylori (H. pylori) are a primary factor in the pathogenesis of gastric cancer (GC); GC ranks third among cancer‐related mortality. A clear understanding of the H. pylori genome factors underlying GC is necessary to develop more effective methods to prevent GC. A single‐molecule real‐time DNA sequencing‐based H. pylori genome‐wide association study analysis was performed using the H. pylori genome present in five early‐stage GC (EGC) and five non‐GC clinical DNA samples recovered...
Mon Aug 17, 2020 13:09
Abstract In Oceania, North America and north‐western Europe, after decades of increase, cutaneous malignant melanoma rates began to stabilise or decline before 2000. Anecdotal evidence suggests that the reversal of the incidence trend is extending to southern Europe. In order to obtain a formal confirmation, this nationwide study from Italy investigated the incidence trends by birth cohort. Twenty‐one local cancer registries covering a population of 15,814,455 provided incidence data for primary...
Mon Aug 17, 2020 13:08
Abstract We investigated the association between metabolic syndrome (MetS) and its components and risk of prostate cancer (PCa) in a cohort of men enrolled in the UK Biobank. Our study cohort included 220 622 PCa‐free men with baseline measurements of triglycerides (TG), HDL‐cholesterol (HDL), glycated haemoglobin (HbA1c), blood pressure (BP), and waist circumference (WC). Multivariable Cox proportional hazards regression was used to analyse associations with PCa for: individual metabolic components...
Mon Aug 17, 2020 13:08
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Fri Aug 07, 2020 10:00
As metastasis is a major cause of death in cancer patients, new anti-metastatic strategies are needed to improve cancer therapy outcomes. Numerous pathways have been shown to contribute to migration and invasi...
Tue Aug 18, 2020 03:00
Abstract Acquired resistance is a barrier to cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Secreted phosphoprotein 1 (SPP1) is involved in various biological processes, including immune responses, cancer progression, and prognosis in many cancers, while little is known in HNSCC. Bioinformatics methods were used to identify candidate genes and further in vivo and in vitro experiments were performed to examine and validate the function of SPP1. We found that SPP1...
Mon Aug 17, 2020 20:51
Abstract Long noncoding RNAs (LncRNAs) have emerged as important players in cancer biology. Increasing evidence suggests that LncRNAs are frequently dysregulated in cancer and may function as oncogenes or tumor suppressors. Urothelial carcinoma associated 1 (UCA1), a LncRNA, firstly identified in bladder transitional cell carcinoma, seems to act as an oncogene in many different types of human cancers by promoting cell proliferation and migration. In this study, we revealed a novel biological function...
Mon Aug 17, 2020 20:49
Abstract Background The purpose of this review is to summarize our own experimental studies carried out over a 13-year period of time using the F98 rat glioma as model for high grade gliomas. We evaluated a binary chemo-radiotherapeutic modality that combines either cisplatin (CDDP) or carboplatin, administered intracerebrally (i.c.) by means of convection-enhanced delivery (CED) or osmotic pumps, in combination with either synchrotron...
Tue Aug 18, 2020 03:00
Abstract Objectives This pilot trial tested the effect of adding a multi‐level, technology‐based physical activity intervention module to a standard survivorship care plan for breast and colorectal cancer survivors. The objective of this analysis was to determine whether the physical activity module improved health‐related quality of life, sleep, and factors key to lasting behavior change (e.g., social support, self‐efficacy). Methods Breast and colorectal cancer survivors (n=50) were enrolled...
Mon Aug 17, 2020 19:24
Immobilization devices are crucial to minimize patient positioning uncertainties in radiotherapy (RT) treatments. Accurate inter and intra-fraction motions is particularly important for intracranial and stereo...
Tue Aug 18, 2020 03:00
Publication date: October 2020Source: Cancer Epidemiology, Volume 68Author(s): Max Moura de Oliveira, Diego Rodrigues Mendonça e Silva, Fabrícia Rezende Ramos, Maria Paula Curado
Tue Aug 18, 2020 19:07
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου